



HAL
open science

A new triterpenic diester from the aerial parts of *Chrysanthemum macrocarpum*

Naima Boutaghane, Laurence Voutquenne-Nazabadioko, Alain Simon,
Dominique Harakat, Kaddour Benlabeled, Zahia Kabouche

► **To cite this version:**

Naima Boutaghane, Laurence Voutquenne-Nazabadioko, Alain Simon, Dominique Harakat, Kaddour Benlabeled, et al.. A new triterpenic diester from the aerial parts of *Chrysanthemum macrocarpum*. *Phytochemistry Letters*, 2013, 6 (4), pp.519-525. 10.1016/j.phytol.2013.06.009 . hal-01996728

HAL Id: hal-01996728

<https://hal.univ-reims.fr/hal-01996728>

Submitted on 22 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A new triterpenic diester from the aerial parts of

Chrysanthemum macrocarpum

Naima Boutaghane,^{a,b} Laurence Voutquenne -Nazabadioko,^{*a} Alain Simon^c, Dominique Harakat^d, Kaddour Benlabed^e, Zahia Kabouche^b

^a*Groupe Isolement et Structure, Institut de Chimie Moléculaire de Reims (ICMR), CNRS UMR 7312, UFR de Pharmacie, BP 1039, 51687 Reims; France.*

^b*Laboratoire d'Obtention des Substances Thérapeutiques, Faculté des Sciences Exactes, Université de Constantine 1, Chaabet Ersas Campus, 25000 Constantine, Algeria.*

^c*Laboratoire de Chimie Physique Minérale, UPRES EA-1085, Biomolécules et cibles cellulaires tumorales, Faculté de Pharmacie, 2 rue du Dr. Marcland, 87025 Limoges Cedex, France.*

^d*Service Commun d'Analyses, Institut de Chimie Moléculaire de Reims (ICMR), CNRS UMR 7312, Bat. 18 B.P.1039, 51687 Reims Cedex2, France*

^e*Laboratoire de Microbiologie. CHU Ben Badis, Constantine, Algeria.*

* Corresponding author. Tel.: +33 3 26 91 82 09 ; Fax : + 33 3 26 91 31 66.

E-mail adress : laurence.nazabadioko@univ-reims.fr (L. Voutquenne-Nazabadioko)

Abstract

A new triterpenic diester, 3,21-dipalmitoyloxy-16 β ,21 α -dihydroxy- β -amyrine(1), along with two natural cyclitols, conduritol C (2) and viburnitol (3), four known triterpenes (4-7), and seven known flavonoids (8-14) were isolated from the aerial parts of *Chrysanthemum macrocarpum*. Their structures were established on the basis of extensive 1D and 2D NMR (^1H , ^{13}C , COSY, HMBC, HSQC, and ROESY) and ESIMS studies. The chloroform fraction, taraxasterol (4) and β -sitosterol (7) were investigated for their antibacterial activity against *Staphylococcus aureus*, *Enterococcus faecalis*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. The chloroform fraction and taraxasterol (4) showed a weak antibacterial activity and were evaluated for their cytotoxic activity against human colon cancer HT-29 cells and human prostate carcinoma PC3 cells. The results indicated that both the chloroform fraction and taraxasterol (4) inhibited cell proliferation of both PC3 and HT-29 cells.

Keywords:

Chrysanthemum macrocarpum, Asteraceae, Triterpenic diester, Cyclitol, NMR, Antibacterial activity

1. Introduction

The *Chrysanthemum* genus (Asteraceae) is found world-wide and some species have been extensively used as food additives or in traditional medicine to treat inflammation, headache, ulcerative colitis, vertigo, eye irritation, hypertension, and respiratory diseases (Jiangsu, 1993; Yang et al., 2000; Yoshikawa et al., 2000; Matsuda et al., 2002). A series of recent studies have suggested that the *Chrysanthemum* genus possesses a strong anti-cancer and anti-human immunodeficiency virus type 1 (HIV-1) activity. (Ukiya et al., 2002; Lee et al., 2003), Anti-inflammatory (Cheon et al., 2009), antinociceptive (Shi et al., 2011) as well as anti-oxidant activities (Yan et al., 1999) have been also confirmed. The phytochemical profile of *Chrysanthemum* species has shown the presence of terpenoids (Ukiya et al., 2001), flavonoids and phenolic compounds (Lin and Harnyl, 2010). Fifteen *Chrysanthemum* species grow in Algeria (Quezeland Santa, 1963). *Chrysanthemum macrocarpum* (Sch.Bip.)Coss.&Kralik ex Batt., a synonym of *Endopappus macrocarpus* (Coss. & Kralik ex Batt. & Trabut) Sch.Bip., is an endemic species used in traditional medicine as a scabicide and to treat intestinal infections. Touareg people also use this species in food for flavouring and as an herbal tea (Boukef, 1986; Bellakhdar, 1997). We have previously analyzed the chemical composition of the essential oil of this species (Boutaghane et al., 2008). This paper reports the isolation and structural elucidation of one new triterpene fatty acid diester (**1**) and two natural cyclitols, in addition to four known triterpenes, and seven known flavonoids from the aerial parts of *C. macrocarpum* (Fig. 1). The antibacterial activity and cytotoxic activity against HT-29 and PC3 cells of the chloroform soluble fraction and taraxasterol (**4**) were also evaluated in order to obtain an insight into the beneficial effects of this plant species.

2. Results and discussion

The aerial parts of *C. macrocarpum* were extracted with 20% aq. MeOH. After MeOH removal, the crude extract in H₂O was successively partitioned with CHCl₃, EtOAc, and *n*-BuOH. The CHCl₃ soluble fraction was purified by chromatographic separations over silica gel, yielding the new triterpene fatty ester (**1**) and the known compounds identified as taraxasterol (**4**) (Reynolds et al., 1985), stigmasterol (**6**), β-sitosterol (**7**) (Kojima et al., 1990), and calenduladiol-3-*O*-myristate (**5**) (Ukiya et al., 2001) (Fig. 1). The purification of the EtOAc soluble fraction gave the natural cyclitolconduritol C (**2**) (Hiroki et al., 1998) and viburnitol (**3**) (Kindl et al., 1966) along with seven known flavonoids: apigenin (**8**), 7-*O*-methylapigenin (**9**), apigenin-7-*O*-glucoside (**10**) (Bennini et al., 1992), kaempferol-3-*O*-glucoside (**11**), kaempferol-7-*O*-glucoside (**12**) (Kim et al., 2005), luteolin-3'-*O*-glucoside (**13**) (Moiteiro et al., 2008) and 6-*C*-glucosyl-8-*C*-arabinosylapigenin (**14**) (Krafczyk et al., 2008). Their structures were elucidated using chemical and spectroscopic methods including 1D and 2D NMR experiments, and ESIMS.

2.1 Structure elucidation of compounds 1-3

Compound **1** was obtained as a viscous liquid. The HRESIMS (positive ion mode) exhibited a quasimolecular ion peak at m/z 957.8634 [M+Na]⁺ (calc. for C₆₂H₁₁₀O₅Na, 957.8653) suggesting a molecular formula of C₆₂H₁₁₀O₅. The positive ESIMS spectrum gave the same pseudomolecular ion peak at m/z 957 [M+Na]⁺ with a ion fragment observed at m/z 701 [M+Na-C₁₆H₃₂O₂]⁺ in agreement with the loss of a palmitoyloxy side chain. The presence of two acyloxy groups in compound **1** was supported by the presence in the ¹³C NMR spectrum of two carbonyl signals at δ_C 173.3 and 173.7 and in the ¹H NMR spectra of signals due to two methylene groups bearing a carbonyl group at δ_H 2.32 (q'd, $J = 7.1, 1.0$ Hz, H-2') and 2.36 (q'd, $J = 7.7, 2.7$ Hz, H-2''), and for two

terminal methyl groups at δ_{H} 0.90 (6H, t, $J = 7.4$ Hz, H-16' and H-16"). The ^1H NMR spectra of **1** showed the presence of eight methyl singlets at δ 0.81, 0.88, 0.89, 0.91, 1.00, 1.01, 1.02 and 1.27, an olefinic proton at δ 5.33 (t, $J = 3.5$ Hz, H-12), three methine protons bearing an oxygen at δ 4.43 (dd, $J = 11.7, 4.7$ Hz, H-16), 4.53 (dd, $J = 9.3, 5.5$ Hz, H-3) and 4.73 (brt, $J = 3.4$ Hz, H-21) (Table 1). The basic Δ^{12} oleanene skeleton (Mahato and Kundu, 1994) in **1** was supported by the following key HMBC correlations H-3/C-2, C-4, C-5, C-23, C-24; H-12/C-9, C-11, C-13, C-14, C-18; H-16/C-14, C-15, C-17, C-18, C-28; H-21/C-17, C-19, C-20, C-22, C-29, and C-30. The small coupling constant of H-21 (brt, $J = 3.4$ Hz, H-21) indicated an α -axial position for the hydroxyl group, and the large coupling constants of H-16 ($J = 11.7$ Hz) and H-3 ($J = 9.3$ Hz), indicated a β -equatorial position for the hydroxyl groups. In the ROESY experiment, the interaction observed between H-18/H-30 and between H-21/H-30 confirmed the β -equatorial position for H-21. The α -axial orientation of H-3 and H-16 was also confirmed by the ROEs observed between H-3 and H-5 α and H-23 α , while H-16 showed a ROE correlation with H-27 α . Thus, the aglycone of compound **1** was determined to be 3 β ,16 β ,21 α -trihydroxy-olean-12 ene. The downfield shifts of H-3 and H-21 at δ_{H} 4.53 and 4.73, respectively in **1** suggested the esterification of the secondary hydroxyl groups at C-3 and C-21 by two acyloxy groups. This was confirmed by the HMBC correlations observed between H-3 (δ_{H} 4.53) and the carbonyl carbon signal of the first acyloxy side chain (δ_{C} 173.7), and between H-21 (δ_{H} 4.73) and the second carbonyl carbon signal (δ_{C} 173.3). The two acyloxy groups were identified by ESIMS as being palmitic acid esters. Subtraction of the triterpene unit from the molecular formula of the ion fragment at m/z 701 $[\text{M}+\text{Na}-\text{C}_{16}\text{H}_{32}\text{O}_2]^+$ indicated that the second fatty acid ester was identical and correspond to a palmitic acid. Another ion fragment observed at m/z 685 $[\text{M}+\text{Na}-\text{HO}-\text{C}_{16}\text{H}_{32}\text{O}_2]^+$ indicated the simultaneously loss of the

palmitic acid in C-21 position and OH in C-16 position. Thus, compound **1** was identified as 3,21-dipalmitoyloxy-16 β ,21 α -dihydroxy- β -amyrine.

Compound **2** was obtained as colourless crystals and afforded a $[M+Na]^+$ quasimolecular ion peak at m/z 169 suggesting the molecular formula of $C_6H_{10}O_4Na$. In the ^{13}C NMR spectrum, six carbon signals were observed at δ_C 66.6, 71.2, 72.4, 72.5, 126.6 and 132.4, and the corresponding 1H signals were observed at δ_H 3.95, 3.64, 4.20, 3.43, 5.83 and 5.75, respectively (Table 2). The 1H - 1H COSY spectrum of **2** showed a cyclic spin system with correlations observed between the olefinic protons at δ_H 5.75 and δ_H 5.83 and both protons H-4 (δ_H 4.20) and H-1 (δ_H 3.95). H-4 and H-1 were also correlated with H-3 (δ_H 3.43) and H-2 (δ_H 3.64), respectively, and H-2 with H-3, suggesting a cyclohexenetetraol. In the HMBC spectrum H-4 and H-1 correlated with C-5 and C-6 indicating that the double bond was located in the C-5 (6) positions. The small coupling constant of H-4 (t, $J = 4.5$ Hz) indicate an α -configuration of the hydroxyl group. The large coupling constants up to 7 Hz for protons H-1, H-2 and H-3 indicate a β -configuration for the three hydroxyl groups in these positions. Therefore, **2** was deduced as being cyclohex-5-ene 1 β ,2 β ,3 β ,4 α -tetraol, also named conduritol C previously obtained by synthesis (Balci et al., 1990). To our knowledge, this is the first time that this compound has been isolated in a natural product.

Compound **3** displayed a quasi-molecular ion peak at m/z 187 $[M+Na]^+$ indicating a molecular weight of 164 which is 18 mass units greater than that of **2** and suggesting a molecular formula of $C_6H_{12}O_5$. Careful comparison of the NMR spectroscopic data of **3** with that of **2** (Table 2) showed in the 1H and ^{13}C NMR signals of **3**, the absence of the two olefinic carbon signals at δ_C 126.6 and 132.4 and the occurrence of hydroxyl group (δ_H 4.02/ δ_C 69.6) and methylene carbon at δ_C 37.1. Full examination of the 2D NMR

spectroscopic data further confirmed the structure of compound **3** as cyclohexa-1 β ,2 α ,3 β ,4 α ,5 α -pentaol also named viburnitol (Kindl, H., et al., 1969).

2.2 Antibacterial and cytotoxic activities

The antibacterial activity of the CHCl₃ soluble fraction, EtOAc soluble fraction, *n*-BuOH soluble fraction, and compounds **4** and **7** was performed using the disc diffusion method against two Gram-positive (*S. aureus* and *E. faecalis*) and three Gram-negative (*E. coli*, *P. aeruginosa*, *K.pneumoniae*) bacteria (Table 3). The chloroform fraction and **4** and **7** were further analyzed by TLC-direct bioautography on silica gel GF₂₅₄ to determine the number of active compounds. As observed with the disc diffusion method, the assay for bioautography demonstrated weak inhibition zones of chloroform fraction and taraxasterol (**4**) against the growth of Gram-negative (*E. coli*, *P. aeruginosa*, *K.pneumoniae*) bacteria. The clear zones were located separately on TLC suggesting that more than one compounds at different R_f values involved in antibacterial effects. Nevertheless, no inhibition zone was observed with compound **7** at the concentration tested. Minimum inhibitory concentration (MICs) determination was performed by the serial dilution method (Table 3), ampicillin was used as a positive control in these tests. Only the CHCl₃ fraction of *C. macrocarpum* notably inhibited the growth of all the tested bacteria (Gram-positive and Gram negative), and was shown to possess the strongest antibacterial activity against Gram negative with the largest inhibition zones (30 and 24 mm for *P. aeruginosa* and *E. coli*, respectively) and lowest MICs 0.5 to 8 μ g/ml. Compound **4** also showed relatively modest activity, most particularly against Gram negative bacteria *K. pneumonia* (32 μ g/ml), *E. Coli* (32 μ g/ml) and *P. aeruginosa* (16 μ g/ml). Previous findings have shown that taraxasterol exhibited antibacterial properties (Singh et al., 2002; Singh and Dubey, 2001; Villarreal et al., 1994; Dai et al., 2001). The antibacterial activity of the chloroform fraction could,

in part, be associated with the triterpenes such as taraxasterol (**4**), the main component of the chloroform fraction. In fact, it was also possible that the components in lower percentage might be involved in some type of synergism with the other active compounds. Our results support the use of *C. macrocarpum* in traditional medicine for diseases caused by infective agents.

To determine the cytotoxicity of the chloroform soluble fraction of *C. macrocarpum* and taraxasterol (**4**), cell proliferation was evaluated by MTT assay on two cell lines, the human HT-29 colorectal cancer cell line and the human PC3 prostate cancer cell line. The chloroform fraction and taraxasterol inhibited cell proliferation of both HT-29 and PC3 cancer cells in a dose- and time-dependent manner. The IC₅₀ were calculated on PC3 and HT-29 cells at 48h as being 69.3 and 103.1 µg/ml, respectively, for chloroform fraction and 37.1 µM and 89.7 µM, respectively, for taraxasterol (**4**) (Table 4). Taraxasterol seems to be responsible of the activity of the extract. It is known to possess antiproliferative activity against various cancer cells (Villarreal et al., 1994; Dai et al., 2001).

In conclusion, a new triterpenic diester, 3,21-dipalmitoyloxy-16β,21α-dihydroxy-β-amyryne(**1**), and two natural cyclitols, conduritol C (**2**) and viburnitol(**3**), together with four known triterpenes, and seven known flavonoids were isolated from the aerial parts of *Chrysanthemum macrocarpum*. This study clearly show that the chloroform fraction presents a good activity against Gram-negative bacteria (*P. aeruginosa*, *K. pneumonia*, *E. coli*) with MICs values of 0.5, 4 and 8 µg/ml, respectively, better than ampicilline used as control. At these concentrations, no cytotoxic activity was observed on PC3 and HT-29 cells. It can be concluded that this plant may serve as a very good source of potential antibacterial agent and justify their used in traditional medicine as scabicides and for the treatment of intestinal infections.

3. Experimental

3.1. General experimental procedures

Optical rotations were measured in MeOH or CHCl₃ with a Perkin-Elmer 241 polarimeter. ¹H and ¹³C NMR spectra were recorded on a BrukerAvance DRX 500 NMR spectrometer (¹H at 500 MHz and ¹³C at 125 MHz). 2D-NMR experiments were performed using standard Bruker microprograms. Coupling constants were expressed in Hz, and chemical shifts were given on a δ (ppm) scale. ESIMS and HR-ESIMS experiments were performed using a Micromass Q-TOF micro instrument (Manchester, UK). The samples were introduced by direct infusion in a solution of MeOH at a rate of 5 μL min⁻¹. TLC was carried out on precoated silica gel 60 F₂₅₄ (Merck), and spots were visualized by heating after spraying with 50% H₂SO₄. Kieselgel 60 (63-200 mesh) Merck or LiChroprep RP-18 (40-63 μm) Merck silica gel were used for Column chromatography (CC). HPLC was performed on a Dionex apparatus equipped with an ASI-100 autosampler, a P580 pump, a UVD 340S diode array detector, and Chromeleon[®] software. A prepacked RP-18 column (201SP510, 250 × 10 mm, 5 μm, 90 Å, Dionex, Vydac, France) was used for semi preparative HPLC of the flavonoids with a binary gradient elution (solvent A: H₂O with 0.0025% TFA, solvent B: MeCN) at 25 °C and a flow rate of 3.5 mL min⁻¹; the chromatogram was monitored at 254 and 365 nm. The following reagents were used for cell culture assay: DMEM and foetal calf serum (Gibco BRL, Cergy-Pontoise, France), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and sodium dodecyl sulfate (SDS) (Sigma Chemical Co., St. Louis, MO).

3.2. Plant material

The aerial parts of *Chrysanthemum macrocarpum*(Sch.Bip.) Coss.&Kralik ex Batt.were collected in the flowering season from Ghardaia (Algerian septentrionalsahara) in April 2005. The botanical determination was performed by Pr Gérard De Bélair from Annaba-University (Algeria). A voucher specimen has been deposited in the botanic Museum of Angers, France under reference MBAng 2005-8.

3.3 Extraction and isolation

Dried and powdered aerial parts (1380 g) of *C. macrocarpum* were macerated in 20% aq. MeOH (10 l). The hydromethanolic extract was concentrated to dryness (under low pressure). The residue was suspended in H₂O and successively partitioned with CHCl₃, EtOAc, and *n*-BuOH (3 ×300 ml, each), respectively, affording a CHCl₃ soluble fraction (20 g), an EtOAc-soluble fraction (4 g), and a *n*-BuOH-soluble fraction (20 g). A part (10 g) of the CHCl₃ soluble fraction was fractionated by silica gel CC, using a gradient of cyclohexane-EtOAc (1:0 to 0:1) to give 20 fractions. The fraction 6 (964 mg) eluted with cyclohexane-EtOAc (95:5) was fractionated by silica gel CC eluted with a gradient of cyclohexane-CHCl₃ (1:0 to 8:2). Fractions 71-99 (290 mg), eluted with cyclohexane-CHCl₃ (9:1) were subjected to silica gel CC using 100% toluene as solvent, and then fractions 62-75 (141 mg) were further purified by TLC preparative in toluene-acetone (98:2) to give compound **1** (6.5 mg). The fraction 9 (680 mg) was submitted to silica gel CC using a gradient of toluene-acetone (1:0 to 8:2) to give taraxasterol **4** (30 mg). Preparative TLC of fractions 36-50 (24 mg), eluted with toluene-acetone (98:2), developed with a mixture of toluene-acetone (96:4), give taraxasterol **4** (2.3 mg), and calenduladiol-3-*O*-myristate **5** (8 mg). A part of fraction 12, eluted with cyclohexane-EtOAc (8:2) was subjected to silica gel vacuum liquid chromatography (VLC) using a gradient of cyclohexane-EtOAc (9:1 to 6:4). Three fractions of 150 ml were collected and monitored by TLC in cyclohexane-EtOAc (8:2).

Fraction 2 was subjected to silica gel CC using petroleum ether-EtOAc (1:0 to 8:2) to give stigmasterol **6** (15 mg) and β -sitosterol **7** (25 mg) in pure form.

The EtOAc soluble extract was fractionated by silica gel CC, using a gradient of CHCl₃-MeOH (1:0 to 0:1). Fractions 7-9 (150 mg), eluted with CHCl₃-MeOH (95:5) were purified by silica gel CC eluted with EtOAc-MeOH (99:1 to 8:2) to provided apigenin **8** (13 mg) and 7-*O*-methyl-apigenin **9** (10 mg). Fractions 13-16 (491 mg), eluted with CHCl₃-MeOH (9:1), were fractionated by silica gel CC using a gradient of EtOAc-MeOH (1:0 to 6:4) to afforded fifteen fractions. Fractions eluted with EtOAc-MeOH (85:15) were submitted to reversed-phase (RP-18) CC, using a gradient of MeOH-H₂O (6:4 to 1:0) as eluent, to yield conduritol C **2** (27 mg) and apigenin-7-*O*-glucoside **10** (30 mg). The purification of 25 mg of fraction 17, using the same conditions, afforded viburnitol **3** (4.4 mg). Fractions 18-21 (108 mg), eluted with CHCl₃-MeOH (85:15), were purified by semi-preparative HPLC, using a linear gradient (15 to 20 % B during 20 min) at 4 ml/min to give kaempferol-3-*O*-glucoside **11** (*t*_R 9.01 min, 3.5 mg), kaempferol-7-*O*-glucoside **12** (*t*_R 12.34 min, 5.5 mg), and luteolin-3'-*O*-glucoside **13** (*t*_R 11.24 min, 3.7 mg). Fraction 22 (25 mg) eluted with CHCl₃-MeOH (8:2), gave 6-*C*-glucosyl-8-*C*-arabinosylapigenin **14** (*t*_R 20.19 min, 7 mg), by semi-preparative HPLC using a linear gradient (10 to 20 % B during 22 min) at 4 ml/min.

3.3.1 Compound **1**

Colourless viscous liquid; ¹H and ¹³C NMR, see Table 1; HRESIMS (positive-ion mode) *m/z*: 957.8634 [M+Na]⁺ (calcd for C₆₂H₁₁₀O₅Na: 957.8653); ESIMS (positive-ion mode) *m/z*: 957 [M+Na]⁺, 701 [M+Na-C₁₆H₃₂O₂]⁺, 685 [M+Na-OH-C₁₆H₃₂O₂]⁺; [α]_D²⁰+11.5° (*c* 0.76, CHCl₃).

3.3.2 Conduritol C (**2**)

Colourless crystals; ^1H and ^{13}C NMR, see Table 2; ESIMS (positive-ion mode) m/z : 169 $[\text{M} + \text{Na}]^+$; $[\alpha]_{\text{D}}^{20}$ 209.5° (c 0.27, MeOH).

3.3.3 Viburnitol (3)

Colourless crystals; ^1H and ^{13}C NMR, see Table 2; ESIMS (positive-ion mode) m/z : 187 $[\text{M} + \text{Na}]^+$.

3.4 Antibacterial activity

American Type of Culture Collection (ATCC) standard against namely: *Staphylococcus aureus* (ATCC 25923), *Enterococcus faecalis* (ATCC 29212) and Gram negative *Escherichia coli* (ATCC 25922), *Pseudomonas aeruginosa* (ATCC 27853) and the clinically isolated strain *Klebsiella pneumonia* were used. The reference strains were obtained from the Pasteur Institute (Algiers). The clinical strain was obtained from the laboratory of bacteriology, Benbadis Hospital, Constantine, using conventional methods (clinical isolation).

3.4.1. Antibacterial screening

The disk diffusion assay was used with some modifications (Rasoanaivo and Ratsimamanga, 1992; NCCLS, 1997) to determine the growth inhibition of bacteria by the CHCl_3 soluble fraction, EtOAc soluble fraction, n -BuOH soluble fraction and compounds **4** and **7** of *C. macrocarpum*. The bacteria tested were maintained at 4 °C on nutrient agar (NA). Base plates were prepared by pouring 10 ml Mueller–Hinton (MH) agar into sterile petri dishes (9 cm) and allowed to set. Molten MH agar held at 48 °C was inoculated with a broth culture (10^6 – 10^8 bacteria per ml) of the test organism and poured over the base plates forming a homogenous top layer. Paper discs (Whatman No. 3, 6mm diameter) were sterilized by autoclaving. 10 μl of the fractions or compounds **4** and **7** (128 mg/10ml) were applied to paper disc so that each disc contains 128 μg of sample. After evaporation of the solvent in a sterile atmosphere, paper discs were placed

in the top layer of the MH agar plates. The fractions were tested in triplicate, with ampicillin ($10 \mu\text{g ml}^{-1}$) and ceftazidime ($30 \mu\text{g ml}^{-1}$) disc as reference. The plates were evaluated after incubation at 37°C for 18 h. The results were recorded by measuring the diameter of inhibition zone at the end of 18 hours.

3.4.2. Thin-layer chromatography-direct bioautography

Thin-layer chromatography (TLC)-direct bioautographic method (Shai et al., 2008) was applied to identify and localize active compounds in the chloroform fraction against *Pseudomonas aeruginosa*, *Escherichia coli* (ATCC 25922), *Staphylococcus aureus* (ATCC 25923), *Enterococcus faecalis* (ATCC 29212) and *Klebsiella pneumoniae*. The chloroform fraction or the compounds **4** and **7** were dissolved in chloroform at a concentration of 1 mg/ml. 100 μl of the chloroform fraction or 50 μl of **4** and **7** were spotted at 1 cm from the base of preparative Merck chromatography silica gel 60 F₂₅₄ TLC plates. TLC plate loaded with the chloroform fraction and the pure compounds was developed in a hexane: ethyl acetate (8:2, v/v) solvent system. After migration, the solvent was evaporated. TLC plates were overlapped homogeneously with 10 ml of nutrient agar (Mueller-Hinton) infected by nutrient broth containing bacteria (10^8cfu/ml). After solidification of the medium, the TLC plates were incubated for 24 h at 37°C . Subsequently, bioautograms developed were sprayed with 2 mg/ml of *p*-iodonitrotetrazolium bromide (INT) (Sigma). Clear zones on bioautograms indicated inhibition of growth after incubating for 2 h at 37°C .

3.4.3 Determination of the minimums inhibitory concentrations (MICs).

Tests were performed by the agar dilution method according to the NCCLS with some modifications. The CHCl_3 soluble fraction or compounds **4** and **7** were dissolved in ethanol to a final concentration of 512 $\mu\text{g/ml}$. This was serially diluted 2 fold with MH medium to obtain concentration of 0.5, 1, 2, 4, 8, 16, 32, 64 and 128 $\mu\text{g/ml}$. 2 ml of each

concentration was added in Petri dished containing 18 ml of MH medium previously inoculated with suspension of bacteria (10^5 CFU/ml) for testing the samples. Control plates contain the culture medium and 2 % of ethanol. Plates were incubated at 37 °C for 18hours. The minimum inhibitory concentration (MIC) was defined as the concentration at which no colony was observed after incubation. All experiments were performed in triplicates.

3.5 Cell culture and cell proliferation assay (MTT)

Human colorectal cell line HT-29 and human prostate carcinoma PC3 cells were purchased from American Type Culture Collection (LGC Standards, Middlesex, UK). Cells were seeded at $3 \cdot 10^4$ /cm² and grown in DMEM, supplemented with 10% foetal calf serum, 100 units/ml of penicillin, 100 mg/ml of streptomycin. Cells were incubated under 5% CO₂ humidified atmosphere at 37 °C. Cell viability was determined by the trypan blue dye exclusion method.

The effect of the chloroform fraction of *C. macrocarpum* and the isolated taraxasterol (**4**) on cell viability was assessed using the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay, as described previously (Mosmann, 1983). This test is based on the ability of the mitochondrial succinate deshydrogenase enzyme of living cells to reduce MTT to a purple-blue insoluble formazan precipitate. The HT-29 and PC3 cells were plated in 96-well plates at concentration of 10^4 cells/well and incubated for 24 h, then treated with various concentrations of chloroform fraction or **4** or ursolic acid used as positive control which were dissolved in dimethyl sulfoxide (DMSO) and diluted with culture medium to give the appropriate final concentrations of 20-140 µg/ml. Controls were done with the same final DMSO concentration in the medium as samples. After incubation of the cells with chloroform fraction for 24 or 48 h or with **4** for 48 hat 37 °C, 10 µl of 5 mg/ml MTT solution were added to each well

and incubated for 4 h at 37 °C. Then, 100 µl of 10% sodium dodecyl sulfate (SDS) in 0.01 M HCl was added to each well. The degree of formazan formation, an indicator of living and metabolically active cells, was determined using ELISA reader at 550 nm. Six wells per dose and time point were measured in 3 different experiments.

Acknowledgments

We wish to thank the Ministry of Higher Education and Scientific Research (Algeria) for financial support. Financial support by CNRS, Conseil Regional Champagne Ardenne, Conseil General de la Marne, Ministry of Higher Education and Research (MESR) and EU-programme FEDER to the PLANET CPER project is gratefully acknowledged. The authors are very grateful to Karen Ple (ICMR) for revising the English.

References

- Balci, M., Sütbeyaz, Y., Secen, H. 1990. Conduritols and related compounds. *Tetrahedron*, 46: 3715–3742.
- Bellakhadar, J., 1997. *La pharmacopée marocaine traditionnelle*, Ibis Press.
- Bennini, B., Chulia, A.J., Kaouadji, M., Thomasson, F., 1992. Flavonoid glycosides from *Erica cinerea*. *Phytochemistry* 31, 2483–2486.
- Boukef, M.K., 1986. *Les plantes dans la médecine traditionnelle tunisienne*, Collection: agence de cooperation culturelle et technique.
- Boutaghane, N., Kabouche, A., El-Azzouny, A. M., Kabouche, Z., 2008. Composition of the essential oil of *Chrysanthemum macrocarpum* from Algeria. *Chem. Nat. Compounds* 44, 817-818.

Cheon, M.S., Yoon, T., Lee, D.Y., Choi, G., Moon, B.C., Lee, A.-Y., Choo, B.K., Kim, H.K., 2009. *Chrysanthemum indicum* Linne extract inhibits the inflammatory response by suppressing NF-kappa B and MAPKs activation in lipopolysaccharide-induced RAW 264.7 macrophages. *J. Ethnopharmacol.* 122, 473–477.

Dai, J., Zhao, C., Zhang, Q., Liu, Z.L., Zheng, R., Yang, L., 2001. Taraxastane-type triterpenoids from *Saussurea petrovii*. *Phytochemistry* 58, 1107-1111.

Hiroki, Y., Jan-E, B., 1998. Efficient synthesis of (+), and (-) conduritol C via Palladium (II) catalyzed 1,4-Diacetoxylation in combination with enzymatic hydrolysis. *J. Org. Chem.* 63, 9339–9341.

Jiangsu new medical college, 1993. In: Dictionary of chinese materia medica science and technology, Shanghai press, pp 2144–2145.

Kim, M.-Y., Kim, Y.-C., Chung, S.-K., 2005. Identification and *in vitro* biological activities of flavonols in garlic leaf and shoot: inhibition of soybean lipoxygenase and hyaluronidase activities and scavenging of free radicals. *J. Sci. Food Agric.* 85, 633–640.

Kindl, H., Hoffmann-Ostenhof, O., 1966. Untersuchungen über die biosynthese der cyclite—XIII: Vorkommen and biosynthese von cycliten in Asclepiadaceae. *Phytochemistry* 5, 1091-1102.

Kojima, H., Sato, N., Hatano, A., Ogura, H., 1990. Sterol glucosides from *Prunella vulgaris*. *Phytochemistry* 29, 2351–2355.

Krafczyk, N., Kotke, M., Lehnert, N., Glomb, M., 2008. Phenolic composition of rhubarb. *Eur. Food Res. Technol.* 228, 187–196.

Lee, J.S., Kim, H.J., Lee, Y.S., 2003. A new anti-HIV flavonoid glucuronide from *Chrysanthemum morifolium*. *Planta Med.* 69, 859–861.

Lin L.-Z., Harnyl, J.M., 2010. Identification of the phenolic components of *Chrysanthemum* flower (*Chrysanthemum morifolium* Ramat). Food chem. 120, 319–326.

Mahato, S.B., Kundu, A.P., 1994.¹³C NMR spectra of pentacyclic triterpenoids. A compilation and some salient features. Phytochemistry 37, 1517–1575.

Matsuda, H., Morikawa, T., Toguchida, I., Harima, S., Yoshikawa, M., 2002. Medicinal flowers VI. Absolute stereostructures of two new flavanone glycosides and a phenylbutanoid glycoside from the flowers of *Chrysanthemum indicum* L: their inhibitory activities for rat lens aldose reductase. Chem. Pharm. Bull.50, 972–975.

Moiteiro, M., Gaspar, H., Rodrigues, A.I., Lopes, J.F., Carnide, V., 2008. HPLC quantification of dye flavonoids in *Reseda luteola* L. from Portugal. J. Sep. Sci.31, 3683–3687.

Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods65, 55–63.

NCCLS (National Committee for Clinical Laboratory Standards), 1997. Performance standards for antimicrobial disk susceptibility test, 6th ed. Approved standard. M2-A6, Wayne, PA.

Quezel et Santa., 1963. In : La Nouvelle Flore de l'Algérie et des Régions Désertiques Méridionales, Tome II, C.N.R.S. ed., Paris, pp 982-988.

Rasoanaivo, P., Ratsimamanga-Urveg, S., 1993. In: Monograph of the IFS-NAPRECA Workshop on Bioassays, Antananarivo, Madagascar, pp72–79.

Reynolds, W.F., Sawyer, J.F., Enriquelez, R.G., Escobar, L.I. Chaveez, M.A., Shoolery, J.N., 1985. Total assignment of the ¹³C spectrum of taraxasteryl acetate by ¹³C-¹³C connectivity experiments and determination of the stereochemistry of taraxasterol by X-ray diffraction.Can. J. Chem.63, 1048–1054.

Shai, L. J., McGaw, L.J., Aderogba, M.A., Mdee, L.K., Eloff, J.N., 2008. Four pentacyclitriterpenoids with antifungal and antibacterial activity from *Curtisiadentata* (Burm.f) C.A. Sm. leaves. *J. Ethnopharmacol.* 119, 238–244.

Shi, G.-B., Zhao, M.-H., Zhao, Q.-C., Huang, Y., Chen, Y.-F., 2011. Mechanisms involved in the antinociception of petroleum ether fraction from the EtOH extract of *Chrysanthemum indicum* in mice. *Phytomedicine* 18, 609–616.

Singh, B., Dubey, M., 2001. Estimation of triterpenoids from *Heliotropium marifolium* Koen ex. Retz. *in vivo* and *in vitro*. I. Antimicrobial screening. *Phytother. Res.* 15, 231–234.

Singh, B., Sahu, P.M., Sharma, M.K., 2002. Anti-inflammatory and antimicrobial activities of triterpenoids from *Strobilanthes callosus* Nees. *Phytomedicine* 9, 355–359.

Ukiya, M., Akihisa, T., Yasukawa, K., Kasahara, Y., Kimura, Y., Koike, K., Nikaido, T., Takido, M. 2001. Constituents of Compositae Plants. 2. Triterpenediols, triols, and their 3-*O*-fatty acid esters from edible *Chrysanthemum* flower extract and their anti-inflammatory effects. *J. Agric. Food Chem.* 49, 3187–3197.

Ukiya, M., Akihisa, T., Tokuda, H., Suzuki, H., Mukainaka, T., Ichiishi, E., Yasukawa, K., Kasahara, Y., Nishino, H. 2002. Constituents of Compositae plants III. Anti tumor promoting effects and cytotoxic activity against human cancer cell lines of triterpene diols and triols from edible *Chrysanthemum* flowers. *Cancer Lett.* 177, 7–12.

Villarreal, M.L., Alvarez, L., Alonso, D., Navarro, V., Garcia, P., Delgado, G., 1994. Cytotoxic and antimicrobial screening of selected terpenoids from Asteraceae species. *J. Ethnopharm.* 42, 25–29.

Yan, Y.C, Lou, X.E, Jiang, H.D., 1999. Experimental studies on the anti-oxidant effects of water extract from *Chrysanthemum indicum*. *ZhongGuo Xian Dai Ying Yong Yao XueZaZhi* 16, 16–18.

Yang, Z.G., Ren, A.N., Xu, L., Sun, X.J., Hua, X.B., 2000. Experimental study on the immunological and anti-inflammatory activities of *Chrysanthemum indicum*. Chinese journal of traditional Medical science and technology 2, 92–93.

Yoshikawa, M., Morikawa, T., Toguchida, I., Harima, S., Matsuda, H., 2000. Medicinal flowers. II. Inhibitors of nitric oxide production and absolute stereostructures of five new germacrane-type sesquiterpenes, kikkanols D, D monoacetate, E, F, and F monoacetate from the flowers of *Chrysanthemum indicum* L. Chem. Pharm. Bull. 48, 651–656.

Table 1. ^1H and ^{13}C NMR Spectroscopic Data (CDCl_3) of compound **1**

1					
position	δ_{C}	δ_{H} (J in Hz)		δ_{C}	δ_{H} (J in Hz)
1a	38.3	1.09, m	Acyl in C-3		
1b		1.65, m			
2a	23.6	1.66, m	1'	173.7	
2b		1.92, m			
3	80.5	4.53, dd (9.3, 5.5)	2'	34.9	2.32, q'd (7.1, 1.0)
4	37.8		3'	25.2	1.65, m
5	55.3	0.88, m	4'- 13'	29.1- 29.9	1.28, brs
6a	18.2	1.44, m	14'	31.9	1.28, m
6b		1.58, m			
7a	32.9	1.37, m	15'	22.7	1.32, m
7b		1.56, m			
8	39.8		16'	14.2	0.90, t (7.4)
9	46.8	1.58, m	Acyl in C-21		
10	36.8		1"	173.3	
11	23.6	1.97, m	2"	34.9	2.36, q'd (7.7, 2.7)
12	122.9	5.33, brt (3.5)	3"	25.2	1.67, m
13	142.9		4"- 13"	29.1- 29.9	1.28, brs
14	43.9		14'	31.9	1.28, m
15a	35.4	1.65, m	15"	22.7	1.32, m
15b		1.29, m			
16	68.3	4.43, dd (11.7, 4.7)	16"	14.2	0.90, t (7.4)
17	37.4				
18	48.5	2.28, dd (14.1, 4.2)			
19a	42.1	1.06, m			
19b		2.11, t (13.8)			
20	34.3				
21a	76.5	4.73, brt (3.4)			
21b					
22a	34.1	1.39, dd (15.7, 3.3)			
22b		2.17, dd (15.7, 3.1)			
23	28.1	0.91, s			
24	16.8	0.89, s			
25	15.6	1.00, s			
26	16.8	1.01, s			
27	26.7	1.27, s			
28	21.4	0.81, s			
29	27.4	0.88, s			
30	24.8	1.02, s			

Table 2. ^1H and ^{13}C NMR Spectroscopic Data (CD_3OD) of compounds **2-3**

2		3	
δ_{C}	$\delta_{\text{H}}(J \text{ in Hz})$	δ_{C}	$\delta_{\text{H}} (J \text{ in Hz})$
1 66.6	3.95, d (7.5)	69.8	3.81, ddd (14.6, 4.8, 2.7)
2 71.2	3.64, dd (10.4, 7.7)	75.6	3.20, t (9.3)
3 72.5	3.43, dd (10.4, 4.5)	74.3	3.60, t (9.4)
4 72.4	4.20, t (4.5)	79.3	3.42, dd (9.6, 3.0)
5 126.6	5.83, ddd (10.0, 4.5, 2.0)	69.6	4.02, d (2.6)
6 132.4	5.75, dd (10.0, 2.0)	37.1	1.50, ddd (10.0, 2.0)
			2.10 dt (14.4)

Table 3. Minimal Inhibitory Concentration (MIC) and Inhibition Zones of CHCl₃ fraction and compounds **4** and **7** from *Chrysanthemum macrocarpum* against Gram positive and negative bacteria.

Microorganisms	Inhibition Zone diameters (mm)				Ceftazidime	MIC (µg/ml)				
	CHCl ₃ fraction	4	7	Ampicilline		CHCl ₃ fraction	4	7	Ampicilline	Ceftazidime
<i>S. aureus</i>	24	10	12	30		128	128	128	5	
<i>E. faecalis</i>	30	10	10	16		128	128	128	16	
<i>E. coli</i>	24	18	-	18		8	32	>128	10	
<i>P. aeruginosa</i>	30	24	-	-	22	0.5	16	>128	-	16
<i>K. pneumoniae</i>	18	12	-	14		4	32	>128	32	

-, No inhibition zone

Table 4. IC₅₀ of CHCl₃ fraction of *Chrysanthemum macrocarpum* and compound **4** on the proliferation of human PC3 prostate cancer cells line and human colon cancer HT-29 cells line at 24 and 48h

Sample	PC3 (IC ₅₀ , µg/ml)		HT-29(IC ₅₀ , µg/ml)	
	24 h	48 h	24 h	48 h
CHCl ₃ fraction	80.8	69.3	122.4	103.1
Taraxasterol 4	nt	15.8 (37.1 µM)	nt	38.3 (89.7 µM)
Ursolic acid	nt	25 µM	nt	25 µM

nt : not tested at 24h




Fig. 1. Structures of compounds 1–14